The eGenomics system also complements the use of rapid MRSA tests that are being developed by other companies in the industry. "Incorporating the eGenomics system into existing and next generation rapid MRSA tests," adds Dr. Kreiswirth, "would provide hospitals with a system that guides containment and eradication efforts from first admission to final release. Such a combined system would add substantial capability to hospital infection control."
The eGenomics platform incorporates an ever growing proprietary library of over 6000 analyzed S. aureus strains, as well as other infectious organisms.
Dr. Kreiswirth noted that the eGenomics platform is expected to:
-- Reduce the chance of acquiring a nosocomial infection
-- Identify outbreaks and their sources before they become endemic
-- Identify non-outbreaks, allowing hospitals to avoid extreme and costly infection control measures
-- Direct more appropriate antibiotic usage, and thereby extend the effectiveness of existing antibiotics
-- Lower actual costs to control infections
-- Be faster and more accurate than comparable sub-speciation techniques such as Pulsed Field Gel Electrophoresis
-- Share "lessons learned" with participating institutions
-- Allow typically understaffed infection control teams to make infection control decisions based on qualitative data
The eGenomics system is currently being used in active surveillance
programs at Beth Israel Medical Center New York (Continuum Health Care),
Newark (NJ) Beth Israel Medical Center Newark, NJ (St. Barnabas Health Care
System) and the VA Medical Center East Orange NJ. Scientists at the Centers
for Disease Control and Prevention (CDC), Rockefeller University, Duke
University Medical Center, Purdue University, The Institute for Genomic
Research (TIGR) -- as well as research facilities in Australia, Japan,
|SOURCE eGenomics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved